Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
RGNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.04 - $13.48
Previous CloseN/A
Volume155.59K
Average Volume (3M)587.06K
Market Cap
$376.84M
Enterprise Value$371.07M
Total Cash (Recent Filing)$267.87M
Total Debt (Recent Filing)$79.85M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Nov 05, 2025EPS Estimate
-1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding50,514,217
10 Day Avg. Volume673,582
30 Day Avg. Volume587,064
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.47
Price to Sales (P/S)4.59
P/FCF Ratio-2.18
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue2.37
Enterprise Value/Gross Profit3.09
Enterprise Value/Ebitda-2.88
Forecast
1Y Price Target
$25.17Price Target Upside237.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentStrong demand has been noted for enrollment in the pivotal portion of the AFFINITY DUCHENNE study.
Financial ProspectsThe collaboration with AbbVie includes a $100M payment upon the first subject dosed in the upcoming trial and another $100M for the following Phase 3 trial.
Regulatory ProgressThe RGX-121 Biologics License Application is under FDA Priority Review with no observations found during inspections, and it has several advantageous designations like Orphan Drug and Fast Track.
Bears Say
Market ConcernsDemand for DMD gene therapies is expected to decline due to tempered demand for Elevidys.
Safety ConcernsA second acute liver failure-related death in a non-ambulatory DMD patient infused with Elevidys raises concerns in the context of similar therapies.
RegenXBio News
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $5.04 and its highest was $13.48 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is $376.84M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Nov 05, 2025 which is in 85 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Aug 07, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.938 by -$0.442.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -1.3.
How many shares outstanding does RegenXBio have?
RegenXBio has 50,514,217 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.938. Following the earnings report the stock price went down -4.01%.
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in RGNX
RegenXBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.17 (237.40% Upside)
$25.17 (237.40% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 10.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.13%
12-Months-Change
Fundamentals
Return on Equity
-62.49%
Trailing 12-Months
Asset Growth
2.05%
Trailing 12-Months
Company Description
RegenXBio
RegenXBio Inc. is a biotechnology company focused on developing gene therapies for the treatment of various genetic diseases and disorders. The company specializes in its proprietary adeno-associated virus (AAV) gene therapy platform, which is designed to provide long-lasting therapeutic effects by delivering genetic material directly to target cells. RegenXBio's core products include treatments for conditions such as X-linked retinitis pigmentosa, spinal muscular atrophy, and other rare genetic disorders, positioning the company at the forefront of the growing gene therapy market.
RGNX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call revealed a strong start to the fiscal year for REGENXBIO, with significant clinical and financial progress. The company's strategic partnerships and manufacturing capabilities position them well for future commercial success, though regulatory uncertainties and competitive pressures remain challenges.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$25.17
▲(237.40% Upside)
Technical Analysis
Ownership Overview
8.78% Insiders
18.34% Mutual Funds
1.22% Other Institutional Investors
58.27% Public Companies and Individual Investors